Jan 3 (Reuters) - Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
44.11 USD | -5.69% | -7.35% | +98.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+98.07% | 2.5B | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios' blood disorder drug meets goals of late-stage study